Last reviewed · How we verify

NCT05393401: MEPPAVOP

Photoplethysmographic Measurements of Pulse Wave Velocity (PWV) and Blood Pressure (BP)

Recruiting now NA Last updated 2 September 2025
What this trial tests

NA trial testing VOP1k in Healthy Volunteers in 27 participants. Currently enrolling.

Timeline
25 October 2022
Primary endpoint
30 June 2026
30 June 2026

Quick facts

Lead sponsorUniversity Hospital, Grenoble
PhaseNA
StatusRecruiting now
Study typeINTERVENTIONAL
Allocationna
Designsingle group
Maskingnone
Primary purposedevice feasibility
Enrollment27
Start date25 October 2022
Primary completion30 June 2026
Estimated completion30 June 2026
Sites1 location across France

Drugs / interventions tested

Conditions studied

Sponsor

University Hospital, Grenoble

Who can join

18 and older, any sex, with Healthy Volunteers. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Theoretically, there is a correlation between the PWV and the value of the BP, mediated by the distensibility of the segment of artery where the measurements take place. The hypothesis is therefore that the measurement of the PWV through a multisite medical device for detecting the pulse wave by photoplethysmography makes it possible to deduce the value of the BP.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Healthy Volunteers

Currently open trials in the same condition.

Other University Hospital, Grenoble trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05393401.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing